PubRank

Douglas R Lowy

Author PubWeight™ 140.97‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Efficient intracellular assembly of papillomaviral vectors. J Virol 2004 5.36
2 Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol 2015 4.84
3 Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007 4.66
4 Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011 3.92
5 Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 2007 3.88
6 Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 2004 3.85
7 Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol Med 2005 3.26
8 Maturation of papillomavirus capsids. J Virol 2005 3.18
9 HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 2008 3.16
10 Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Nat Genet 2005 2.92
11 Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol 2011 2.85
12 Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov 2011 2.66
13 Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog 2006 2.65
14 Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc Natl Acad Sci U S A 2006 2.64
15 Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 2003 2.58
16 Papillomaviruses infect cells via a clathrin-dependent pathway. Virology 2003 2.47
17 Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression. Proc Natl Acad Sci U S A 2004 2.43
18 E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. EMBO J 2004 2.38
19 Arrangement of L2 within the papillomavirus capsid. J Virol 2008 2.37
20 Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J Virol 2008 2.37
21 Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology 2005 2.31
22 In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe 2010 2.24
23 Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies. J Virol 2008 2.22
24 Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila) 2013 2.17
25 DLC-1:a Rho GTPase-activating protein and tumour suppressor. J Cell Mol Med 2007 2.09
26 Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition. J Virol 2007 2.05
27 Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One 2013 2.03
28 Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst 2009 1.95
29 HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 2011 1.91
30 The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proc Natl Acad Sci U S A 2009 1.90
31 Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities. Proc Natl Acad Sci U S A 2007 1.87
32 Heparan sulfate-independent cell binding and infection with furin-precleaved papillomavirus capsids. J Virol 2008 1.73
33 Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. Vaccine 2006 1.73
34 Effect of Pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model. J Natl Cancer Inst 2011 1.71
35 Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J Infect Dis 2009 1.70
36 Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States. Vaccine 2012 1.61
37 Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol 2012 1.58
38 Rrp1b, a new candidate susceptibility gene for breast cancer progression and metastasis. PLoS Genet 2007 1.55
39 Human alpha-defensins block papillomavirus infection. Proc Natl Acad Sci U S A 2006 1.48
40 Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J Immunol 2002 1.48
41 p16 INK4a gene promoter variation and differential binding of a repressor, the ras-responsive zinc-finger transcription factor, RREB. Oncogene 2003 1.45
42 Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J Infect Dis 2003 1.40
43 Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses. J Clin Invest 2012 1.37
44 Identification of a role for the trans-Golgi network in human papillomavirus 16 pseudovirus infection. J Virol 2013 1.29
45 Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. Vaccine 2005 1.19
46 Inactivation of the Dlc1 gene cooperates with downregulation of p15INK4b and p16Ink4a, leading to neoplastic transformation and poor prognosis in human cancer. Cancer Res 2012 1.14
47 Vaccines to prevent infections by oncoviruses. Annu Rev Microbiol 2010 1.14
48 HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood. Vaccine 2005 1.14
49 The Tensin-3 protein, including its SH2 domain, is phosphorylated by Src and contributes to tumorigenesis and metastasis. Cancer Cell 2009 1.14
50 A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies. Clin Vaccine Immunol 2012 1.13
51 Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. Virology 2006 1.11
52 Prognostic implications of HPV in oropharyngeal cancer. N Engl J Med 2010 1.11
53 Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells. Clin Immunol 2003 1.03
54 Frap, FKBP12 rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor gene. Proc Natl Acad Sci U S A 2003 1.02
55 Getting stronger: the relationship between a newly identified virus and Merkel cell carcinoma. J Invest Dermatol 2009 1.01
56 Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus. J Virol 2004 1.01
57 Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK). Proc Natl Acad Sci U S A 2011 1.00
58 Prevalence of and risk factors for oral human papillomavirus among young women in Costa Rica. J Infect Dis 2013 0.99
59 Prospects for cervical cancer prevention by human papillomavirus vaccination. Cancer Res 2006 0.98
60 Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(®). Vaccine 2012 0.97
61 A new link between Fanconi anemia and human papillomavirus-associated malignancies. J Natl Cancer Inst 2003 0.96
62 Papillomavirus virus-like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells. Eur J Immunol 2005 0.94
63 In vivo longitudinal imaging of experimental human papillomavirus infection in mice with a multicolor fluorescence mini-endoscopy system. Cancer Prev Res (Phila) 2011 0.93
64 Gene expression patterns induced by HPV-16 L1 virus-like particles in leukocytes from vaccine recipients. J Immunol 2009 0.93
65 Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles. Clin Vaccine Immunol 2007 0.92
66 Prevalence of and risk factors for anal human papillomavirus infection among young healthy women in Costa Rica. J Infect Dis 2012 0.92
67 Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine. J Virol 2013 0.92
68 Functional interaction of tumor suppressor DLC1 and caveolin-1 in cancer cells. Cancer Res 2012 0.90
69 Regulation of cell morphology and adhesion by the tuberous sclerosis complex (TSC1/2) gene products in human kidney epithelial cells through increased E-cadherin/beta-catenin activity. Mol Carcinog 2003 0.89
70 Murine skin and vaginal mucosa are similarly susceptible to infection by pseudovirions of different papillomavirus classifications and species. Virology 2012 0.89
71 The expression of glyceraldehyde-3-phosphate dehydrogenase associated cell cycle (GACC) genes correlates with cancer stage and poor survival in patients with solid tumors. PLoS One 2013 0.88
72 Characterization of Mus musculus papillomavirus 1 infection in situ reveals an unusual pattern of late gene expression and capsid protein localization. J Virol 2013 0.87
73 Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial. Hum Vaccin Immunother 2013 0.87
74 Evaluation of two types of sponges used to collect cervical secretions and assessment of antibody extraction protocols for recovery of neutralizing anti-human papillomavirus type 16 antibodies. Clin Vaccine Immunol 2007 0.87
75 Targeting the vaginal mucosa with human papillomavirus pseudovirion vaccines delivering simian immunodeficiency virus DNA. J Immunol 2011 0.86
76 In vitro and in vivo effects of geranylgeranyltransferase I inhibitor P61A6 on non-small cell lung cancer cells. BMC Cancer 2013 0.84
77 Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. Am J Epidemiol 2014 0.82
78 HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions. J Clin Invest 2016 0.81
79 Virus infection and human cancer: an overview. Recent Results Cancer Res 2014 0.81
80 The transcription factor Gfi1 regulates G-CSF signaling and neutrophil development through the Ras activator RasGRP1. Blood 2010 0.81
81 Immune readouts may have prognostic value for the course of merkel cell carcinoma, a virally associated disease. J Clin Oncol 2011 0.75
82 Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay. Hum Vaccin Immunother 2014 0.75